Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center

R. E. Board, C. T P H Bruijns, A. E. Pronk, W. D J Ryder, P. M. Wilkinson, R. Welch, J. H. Shanks, G. Connolly, R. J. Slade, K. Reynolds, H. C. Kitchener, G. C. Jayson

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Current accepted prognostic indicators in ovarian cancer include performance status, surgical (FIGO) staging, and residual disease after operation. Here we present data from a prospective analysis of patients with ovarian cancer treated at the Christie Hospital. We confirm the independent prognostic effects of FIGO staging, performance status, and residual disease in our group of patients and furthermore show that CA125 levels at presentation to the oncology service are of independent prognostic significance (P = 0.02). We present survival data and show that the 3-year, cancer-specific survival for stage I disease is 90%. We postulate that this good survival may in part be due to the use of computed tomography scanning at presentation to allow accurate staging. Further clinical trials are needed to test whether combinations of surgical, histologic, biochemical, and radiologic parameters can be used to identify a population with such a good prognosis that adjuvant therapy is not required. © 2006, IGCS.
    Original languageEnglish
    Pages (from-to)18-24
    Number of pages6
    JournalInternational Journal of Gynecological Cancer
    Volume16
    Issue number1
    DOIs
    Publication statusPublished - Feb 2006

    Keywords

    • CA125
    • Ovarian cancer
    • Stage
    • Survival

    Fingerprint

    Dive into the research topics of 'Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center'. Together they form a unique fingerprint.

    Cite this